Skip to Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Translational Research Program (TRP)
Contact CIP
Show menu
Search this site
Last Updated: 02/21/20

Endometrial SPOREs

Endometrial cancer is the most common cancer of the female reproductive system and accounts for approximately 6 percent of all cancers in women in the United States. Endometrial cancer is typically diagnosed in women aged 45-74, and approximately 65,620 new cases and 12,590 deaths are estimated in the United States in 2020. The first Endometrial SPORE was funded in 2003, and the currently funded Endometrial SPORE at MD Anderson supports four projects focused on developing therapeutic strategies for advanced/recurrent endometrial cancer and aggressive subtypes, addressing unmet clinical needs in prevention and conservative therapy of high-risk precancerous lesions and low grade endometrial cancer, and incorporation of molecular diagnostics into clinical decision-making.